Erik F. Lamberth

Pediatrics

270 Main St
Harleysville, PA 19438

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.

A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.

Journal: Nature communications

Published: April 14, 2026

A human Lyme disease vaccine: two steps forward on the path to prevention.

A human Lyme disease vaccine: two steps forward on the path to prevention.

Journal: Expert review of vaccines

Published: December 22, 2025

Antibody response and safety through 12 months after booster vaccination with an investigational Lyme disease vaccine in adults: a plain language summary.

Antibody response and safety through 12 months after booster vaccination with an investigational Lyme disease vaccine in adults: a plain language summary.

Journal: Current medical research and opinion

Published: October 06, 2025

Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B Clostridioides difficile Vaccine in Adults 50 Years and Older.

Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B Clostridioides difficile Vaccine in Adults 50 Years and Older.

Journal: Open forum infectious diseases

Published: May 13, 2025

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Journal: Human vaccines & immunotherapeutics

Published: February 24, 2025

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 08, 2023

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial.

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial.

Journal: Human vaccines & immunotherapeutics

Published: November 06, 2023

A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.

A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.

Journal: Vaccine

Published: July 24, 2023

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.

Journal: The Pediatric infectious disease journal

Published: September 15, 2021

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

Journal: Vaccine

Published: March 06, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026